Avagacestat (BMS-708163)

  Cat. No.:  DC3114   Featured
Avagacestat (BMS-708163)
Chemical Structure
1146699-66-2
For research use only. We do not sell to patients.
We match the best price and quality on market.
Email:order@dcchemicals.com  sales@dcchemicals.com
Tel:+86-021-58447131
We are official vendor of:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
More than 5000 active chemicals with high quality for research!
Field of application
BMS-708163 is a potent, selective γ-secretase inhibitor of Aβ40 and Aβ42 with IC50 of 0.3 nM and 0.27 nM, respectively.
Cas No.: 1146699-66-2
Chemical Name: (2R)-2-(N-(2-fluoro-4-(1,2,4-oxadiazol-3-yl)benzyl)-4-chlorophenylsulfonamido)-5,5,5-trifluoropentanamide
Synonyms: BMS708163,BMS 708163
SMILES: C(N)(=O)[C@@H](N(CC1=CC=C(C2N=CON=2)C=C1F)S(C1=CC=C(Cl)C=C1)(=O)=O)CCC(F)(F)F
Formula: C20H17ClF4N4O4S
M.Wt: 520.88
Purity: >98%
Sotrage: 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Publication:
Description: Description of Avagacestat (BMS-708163): BMS-708163 (avagacestat) is an oral GSI designed For selective inhibition of Aβ synthesis currently in development For the treatment of mild to moderate and predementia AD. In addition to the desired effect on Aβ synthesis, GSIs affect Notch processing, which is thought to mediate some toxic adverse effects reported with this drug class. Avagacestat produced up to 190-fold greater selectivity For Aβ synthesis than Notch processing in preclinical studies and may there Fore produce less toxic adverse events than other less selective compounds. Results from this single-ascending dose study suggest that avagacestat was tolerated at a single-dose range of 0.3 to 800 mg and suitable For further clinical development. (source: Clin Ther. 2012 Mar;34(3):654-67. Epub 2012 Feb 28.). For the detailed information about the solubility of BMS-708163 in water, the solubility of BMS-708163 in DMSO, the solubility of BMS-708163 in PBS buffer, the animal experiment(test) of BMS-708163,the in vivo,in vitro and clinical trial test of BMS-708163,the cell experiment(test) of BMS-708163,the IC50, EC50 and Affinity of BMS-708163, please contact DC Chemicals.
In Vivo:
In Vitro:
References:
Kinase Assay:
Cell Assay:
Animal Administration:
References:
MSDS
COA
LOT NO. DOWNLOAD
2018-0101
Cat. No. Product name Field of application
DC5036 LY-411575 LY411575 is a potent γ-secretase inhibitor with IC50 of 0.078 nM/0.082 nM (membrane/cell-based), also inhibits Notch clevage with withIC50 of 0.39 nM.
DC8277 E-2012 E 2012 is a potent γ-secretase modulator.
DC3114 Avagacestat (BMS-708163) BMS-708163 is a potent, selective γ-secretase inhibitor of Aβ40 and Aβ42 with IC50 of 0.3 nM and 0.27 nM, respectively.